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Members of the CD44 family of transmembrane glycoproteins emerge as major signal
transduction control units. CD44 isoforms participate in several signaling pathways rang-
ing from growth factor-induced signaling to Wnt-regulated pathways.The role of the CD44
family members in tumor progression and metastasis is most likely linked to the function
of the various isoforms as signaling hubs. Increasing evidence suggests that these pro-
teins are not solely cancer stem cell (CSC) markers but are directly involved in tumor and
metastasis initiation. It is foreseeable that a link between the expression of CD44 isoforms
in CSCs and their function as signaling regulators will be drawn in a near future.
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The term CD44 designates a large family of transmembrane gly-
coproteins belonging to the class of cell adhesion molecules.
CD44 family members are involved in physiological processes
such as hematopoiesis, lymphocyte homing, or limb development
[reviewed in Ref. (1)]. All CD44 isoforms are encoded by one sin-
gle gene located on chromosome 11 in humans and chromosome
2 in mice [reviewed in Ref. (2)]. The exons 1–5 and 16–20 that
encode the constant part of CD44 are included in all CD44 iso-
forms. Exons 6–15 that encode the variant exons v1–v10 are either
completely excluded as in CD44s or are included in various com-
binations within the CD44 ectodomain, giving rise to the CD44
variant isoforms (CD44v). Of note, exon v1 is not expressed in
human cells due to the presence of a stop codon. The heterogene-
ity of the CD44 family is further increased by several additional
modifications including N- and O-glycosylations.
CD44 EXPRESSION
CD44s is expressed in nearly all tissues whereas the expression
of CD44v isoforms is restricted to specific cell types [reviewed in
Ref. (1) and table in Ref. (3)]. In human skin, the longest CD44
isoform containing the variants v2–v10 can be detected. Expres-
sion of CD44 variants on normal lymphohematopoietic cells is
generally low. T lymphocytes activation by antigen or by mitogen
leads, however, to transient expression of variant isoforms such as
CD44v6 (4, 5). CD44v6 isoforms are also found in proliferative
tissues such as the skin or the intestine (Figure 1).
Overexpression of various CD44 isoforms has been found
in many types of human tumors. A comprehensive review was
published by Naor et al. (6). In colorectal cancer, specific CD44
isoforms are expressed according to the progression of the disease
(7). Isoforms containing the v5 exon could already be detected
in early adenomas. The expression of v6-containing isoforms was
detected in early and advanced polyps as well as in invasive carci-
nomas where it correlated with the Duke stage (7). Interestingly,
a cell-specific splicing was described in the intestine (8). Remark-
ably, the lgr5+ stem cells were shown to be CD44v4-v10+ whereas
transit-amplifying cells exclusively expressed CD44s or smaller
CD44v isoforms but not CD44v4-v10. Human cryptic foci corre-
sponding to microadenomas retaining a stem cell program express
CD44v4-v10 as well but not CD44s. In breast cancer, expression
of CD44v6 was detected in intraductal carcinoma and was related
to tumor invasion, metastasis, and pathological grade (9). CD44s
and CD44v6 were shown to be up-regulated in pancreatic can-
cer adenocarcinoma (10). CD44s expression but not CD44v6 was
associated with worse overall survival. In head and neck cancer
patients, high expression of CD44v6 prompted the development of
a CD44v6 antibody for clinical trial phase I [reviewed in Ref. (2)].
CD44 ACTS AS A SIGNALING HUB
In some cases, the role of CD44 in tumor progression could be
linked to its function as the main receptor for hyaluronan (HA),
a major component of the extracellular matrix (ECM) [reviewed
in Ref. (11)]. This was, for example, the case in breast cancer (12).
The question remains whether other molecular functions of CD44
drive its involvement in specific types of cancers. Accumulating
evidence demonstrate that CD44 acts as a signaling hub control-
ling cell surface receptors of very diverse structure and function,
e.g., CD44v6 isoforms act as co-receptors for RTKs such as Met,
Ron, or VEGFR-2 [reviewed in Ref. (11)]. The function of CD44v6
for these RTKs is a twofold. On one hand, the CD44v6 ectodomain
drives the activation process of the RTK. On the other hand, the
cytoplasmic domain recruits ezrin–radixin–moesin (ERM) pro-
teins together with the cytoskeleton in order to promote signaling
from the RTK. CD44v6 and Met could be found in a complex
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FIGURE 1 | CD44 acts as a co-receptor for several cell surface
receptors including RTKs, G-protein coupled receptors, and LRP6.
Hyaluronan binding to CD44 increases CXCL12-induced CXCR4-G
Protein signaling (18). RTKs activation by their ligands [growth factors
(GFs) such as HGF or VEGF] and downstream signaling are dependent
on CD44v6 [reviewed in Ref. (11)]. In the Wnt-β-catenin pathway, LRP6
recruitment of CD44 leads to β-catenin activation and translocation to
the nucleus (3).
with the Met-ligand HGF (13). Furthermore, Met internalization
was shown to depend on CD44v6 (14). Intriguingly, the func-
tion of the CD44v6 isoform for VEGFR-2 is very similar to the
CD44v6/Met pair. VEGF-induced VEGFR-2 activation depends
on CD44v6 and in addition VEGFR-2-induced signaling requires
the link of CD4v6 to ERMs and to the cytoskeleton (15). Moreover,
CD44v6 and VEGFR-2 could be found in a complex, which was
not inducible by VEGF. Most strikingly, CD44v6-dependent Met
(16) and VEGFR-2 activation (15) could be blocked by small pep-
tides containing a CD44v6 exon sequence; these peptides inhibited
the angiogenesis of pancreatic tumors (15).
A participation of various CD44 isoforms in the activation of
other RTKs (EGFR, PDGFR, or FGFR) was reviewed in Ref. (11).
For example, CD44v3 heparan-sulfated isoforms were shown to
act as a recruitment platform for metalloproteinases like MMP-
7 (or matrilysin) involved in the maturation of HB-EGF and
subsequent activation of ErbB4 (17).
A completely different receptor, namely, CXCR4 also appears to
be dependent of CD44 (18). This time the binding of HA to CD44
is instrumental for this co-operation. High-molecular weight HA
binding to CD44 augmented the activation of CXCR4 by its ligand
CXCL12 whereas small HA fragments completely abrogated the
CXCL12-induced CXCR4 signaling. CD44 and CXCR4 were found
in a CXCL12-dependent complex regulated by HA. Interestingly,
this interaction appears to be crucial for angiogenesis.
More recently, the Wnt-target gene CD44 (19) was shown to
regulate Wnt signaling (3). Overexpression or downregulation
of various CD44 isoforms modulated positively or negatively,
respectively, Wnt activity. Downregulation of CD44 expression
inhibited activation of β-catenin and subsequent translocation to
the nucleus. The role of CD44 in Wnt signaling was indepen-
dent of its binding to HA. In contrast, the binding of the CD44
cytoplasmic domain to ERMs was instrumental. Epistasis experi-
ments revealed a function of CD44 at the level of LRP6 and both
LRP6 and CD44 could be found in a Wnt-inducible complex. The
function of CD44 for LRP6 is dual. On one hand, CD44 con-
trols LRP6 activation, a Wnt-dependent event. On the other hand,
CD44 is involved in LRP6 maturation, a Wnt-independent step.
Indeed, downregulation of CD44 expression lead to a lack of LRP6
membrane expression and to an inhibition of Wnt-induced LRP6
phosphorylation. Downregulation of CD44 in the central nervous
system of Xenopus laevis embryos impaired expression of Wnt-
regulated genes such as eng-2 and tcf-4. CD44 is therefore able to
act as a Wnt-target gene as well as a Wnt regulator.
ALTERNATIVE SPLICING OF CD44 ISOFORMS IN TUMOR
PROGRESSION
Since CD44s and CD44v isoforms are involved in tumor pro-
gression and metastasis alternative splicing of CD44 seems to
be a decisive event controlling the progression of cancer. Sev-
eral years ago, a mini-gene construct was used to investigate
exon v5 alternative splicing and the relevance of signal transduc-
tion for this process was shown (20). The nuclear RNA-binding
protein Sam68 was shown as a decisive factor controlling CD44
splicing (21). This splice regulator was under the direct con-
trol of Erk and consequently under control of Ras confirming
the involvement of growth factor signaling in the regulation of
CD44 alternative splicing. Moreover, a positive feedback loop in
which Ras signaling-induced CD44v6 splicing was unraveled. In
turn, CD44v6 promoted late Ras signaling, which was shown to be
important for cell cycle progression (22).
The regulation of CD44 alternative splicing during tumor pro-
gression is still not completely unraveled. Conversely, the steps
in tumor progression regulated by alternative splicing of CD44

























































Orian-Rousseau CD44 organizes a signaling platform
still need to be defined. Some indications came from studies on
epithelial–mesenchymal transition (EMT). EMT is a process by
which epithelial cells loose their polarity, gain invasive properties,
and acquire mesenchymal features. On one hand, EMT was shown
to induce a CD44+ phenotype (23). On the other hand, a shift from
CD44v to CD44s was essential for cells to undergo EMT as well as
for the formation of breast tumors. In this case, a decreased expres-
sion of the splicing factor epithelial splicing regulator 1 (ESPR1),
which promotes the switch to CD44v isoforms was critical for
EMT. In other studies, the heterogeneous nuclear ribonucleopro-
tein M (hnRNPM) was identified as an essential splicing regulator
involved in TGFβ-induced EMT (24). hnRNPM-mediated CD44
exon skipping was induced through inhibition of ESPR1 function
and was essential for breast cancer metastasis.
In contrast to the above described studies, colonization of the
lung by 4T1 mouse breast cancer cells was shown to be dependent
on the switch from CD44s to CD44v isoforms (25). This time the
knockdown of the EPSR1 protein led to the reduced cell surface
expression of the Na+-independent cystine transporter xCT and
suppressed lung colonization.
In the same line, the activation of the Wnt pathway, a central
player in EMT, induced CD44v6 expression in colorectal cancer
cells [reviewed in Ref. (26)] as well as in breast cancer cells (27).
FUNCTION OF CD44 ON CANCER STEM CELLS
A link between EMT and stemcellness was demonstrated using
immortalized mammary epithelial cells (23). EMT was shown to
generate cells with many of the properties of self-renewing stem
cells. These cancer stem cells (CSCs) that have the ability to seed
a tumor were shown to be CD44+. CD44 is also expressed on
several other types of CSCs including pancreatic and colorectal
CSCs [reviewed in Ref. (28)]. However, little is known on the
molecular function of CD44 in these CSCs. A link between the
presence of specific CD44 isoforms on CSCs and their function
as co-receptors might exist. Several years ago, CD44 and EpCAM
were described as robust markers of colorectal CSCs (29). More
recently, the CD44v4-v10 isoform was detected on lgr5+ stem cells
in the intestinal crypts. The presence of this CD44 isoform on col-
orectal cancer cells was linked to tumor progression in ApcMin/+
mice. The function of CD44 in colorectal cancer might be due
to its role as a modulator of Wnt signaling (3) or as a Wnt-
target gene since one partner of CD44v6, namely the Met RTK,
is also over-expressed in colorectal cancer (30). Met overexpres-
sion could be detected already in dysplastic aberrant crypt foci,
one of the earliest lesions in colorectal cancer. Similarly to CD44,
Met expression seems to be controlled by Wnt. Therefore, col-
laboration between the Wnt-target genes Met and CD44v6 might
be required for the progression of colorectal cancer. This idea was
further strengthened by the finding that the metastatic potential of
colorectal spheres orthotopically injected in the mouse cecum was
abrogated by depletion of CD44v6 and Met (31). Furthermore, in
colorectal CSCs, the expression of CD44 is controlled by several
cytokines including HGF by activating the Wnt pathway thereby
promoting migration and metastasis (31).
Interestingly, circulating primary luminal breast cancer cells
containing a population of metastasis-initiating cells (MICs)
express among other markers Met and CD44 (32). However,
whether any interplay between Met and CD44v6 is necessary for
the metastatic potential of these MICs is not yet clear.
CD44 was suggested as a marker on acute myeloid leukemia
(AML) leukemic stem cells (LSCs) [reviewed in Ref. (28)]. A mAb
(H90) mediating CD44 ligation inhibited AML–LSCs homing to
the bone marrow and their engraftment. The same antibody was
shown to abrogate adhesion of AML CD34+CD38− cells to HA
suggesting that CD44 binding to HA is involved in the homing
process and growth in the bone marrow. Moreover, the interac-
tion between CXCR4 on leukemic cells and CXCL12 in the niche
is needed for the homing and growth of LSCs (33). Taken together,
these data strongly suggest that the molecular function of CD44
and HA in CXCL12-induced signaling (18) might be involved
in AML.
OUTLOOK
For long, the role of CD44 in tumor progression and metasta-
sis remained unclear. Many lines of evidence indicate that CD44
organizes a signaling platform at the cell surface by acting as a
co-receptor for various types of cell surface receptors (Figure 1).
In addition, large amount of data show that CD44 is a bone fide
CSC marker. Understanding whether these two aspects are linked
will require a better knowledge of the functions of CD44 isoforms
at the molecular level and the systematic identification of specific
CD44 isoforms expressed on CSCs. A CD44-based therapy tar-
geting CSCs will certainly benefit from specific tools blocking the
co-receptor function of CD44 for cell surface receptors.
ACKNOWLEDGMENTS
We acknowledge the support by Deutsche Forschungsgemein-
schaft and Open access Publishing Fund of Karlsruhe Institute
of Technology.
REFERENCES
1. Ponta H, Sherman L, Herrlich PA. CD44: from adhesion molecules to signalling
regulators. Nat Rev Mol Cell Biol (2003) 4:33–45. doi:10.1038/nrm1004
2. Orian-Rousseau V. CD44, a therapeutic target for metastasising tumours. Eur J
Cancer (2010) 46:1271–7. doi:10.1016/j.ejca.2010.02.024
3. Schmitt M, Metzger M, Gradl D, Davidson G, Orian-Rousseau V. CD44 func-
tions in Wnt signaling by regulating LRP6 localization and activation. Cell Death
Differ (2014) 22:677–89. doi:10.1038/cdd.2014.156
4. Arch R, Wirth K, Hofmann M, Ponta H, Matzku S, Herrlich P, et al. Participation
in normal immune responses of a metastasis-inducing splice variant of CD44.
Science (1992) 257:682–5. doi:10.1126/science.1496383
5. Koopman G, Heider K-H, Horst E, Adolf GR, Van Den Berg F, Ponta H, et al.
Activated human lymphocytes and aggressive non-Hodgkin lymphomas express
a homologue of the rat metastasis-associated variant of CD44. J Exp Med (1993)
177:897–904. doi:10.1084/jem.177.4.897
6. Naor D, Sionov RV, Ish-Shalom D. CD44: structure, function and association
with the malignant process. In: Vande Woude GF, Klein G, editors. Advances in
Cancer Research. San Diego, CA: Elsevier (1997). p. 243–318.
7. Wielenga VJ, Heider KH, Offerhaus GJ, Adolf GR, Van Den Berg FM, Ponta H,
et al. Expression of CD44 variant proteins in human colorectal cancer is related
to tumor progression. Cancer Res (1993) 53:4754–6.
8. Zeilstra J, Joosten SP, Van Andel H, Tolg C, Berns A, Snoek M, et al. Stem cell
CD44v isoforms promote intestinal cancer formation in Apc(min) mice down-
stream of Wnt signaling. Oncogene (2014) 33:665–70. doi:10.1038/onc.2012.611
9. Liu YJ, Yan PS, Li J, Jia JF. Expression and significance of CD44s, CD44v6,
and nm23 mRNA in human cancer. World J Gastroenterol (2005) 11:6601–6.
doi:10.3748/wjg.v11.i42.6601
10. Li L, Hao X, Qin J, Tang W, He F, Smith A, et al. Antibody against CD44s inhibits
pancreatic tumor initiation and postradiation recurrence in mice. Gastroenterol-
ogy (2014) 146:1108–18. doi:10.1053/j.gastro.2013.12.035

























































Orian-Rousseau CD44 organizes a signaling platform
11. Orian-Rousseau V, Sleeman J. CD44 is a multidomain signaling platform
that integrates extracellular matrix cues with growth factor and cytokine
signals. Adv Cancer Res (2014) 123:231–54. doi:10.1016/B978-0-12-800092-2.
00009-5
12. Yu Q, Stamenkovic I. Transforming growth factor-beta facilitates breast carci-
noma metastasis by promoting tumor cell survival. Clin Exp Metastasis (2004)
21:235–42. doi:10.1023/B:CLIN.0000037705.25256.d3
13. Orian-Rousseau V, Chen L, Sleeman JP, Herrlich P, Ponta H. CD44 is required for
two consecutive steps in HGF/c-Met signaling. Genes Dev (2002) 16:3074–86.
doi:10.1101/gad.242602
14. Hasenauer S, Malinger D, Koschut D, Pace G, Matzke A, Von Au A, et al. Inter-
nalization of Met requires the co-receptor CD44v6 and its link to ERM proteins.
PLoS One (2013) 8:e62357. doi:10.1371/journal.pone.0062357
15. Tremmel M, Matzke A, Albrecht I, Laib AM, Olaku V, Ballmer-Hofer K, et al. A
CD44v6 peptide reveals a role of CD44 in VEGFR-2 signaling and angiogenesis.
Blood (2009) 114:5236–44. doi:10.1182/blood-2009-04-219204
16. Matzke A, Herrlich P, Ponta H, Orian-Rousseau V. A five-amino-acid peptide
blocks Met- and Ron-dependent cell migration. Cancer Res (2005) 65:6105–10.
doi:10.1158/0008-5472.CAN-05-0207
17. Yu WH, Woessner JF, Mcneish JD, Stamenkovic I. CD44 anchors the assembly
of matrilysin/MMP-7 with heparin-binding epidermal growth factor precur-
sor and ErbB4 and regulates female reproductive organ remodeling. Genes Dev
(2002) 16:307–23.
18. Fuchs K, Hippe A, Schmaus A, Homey B, Sleeman JP, Orian-Rousseau V.
Opposing effects of high- and low-molecular weight hyaluronan on CXCL12-
induced CXCR4 signaling depend on CD44. Cell Death Dis (2013) 4:e819.
doi:10.1038/cddis.2013.364
19. Wielenga VJ, Smits R, Korinek V, Smit L, Kielman M, Fodde R, et al. Expression
of CD44 in Apc and Tcf mutant mice implies regulation by the WNT pathway.
Am J Pathol (1999) 154:515–23. doi:10.1016/S0002-9440(10)65297-2
20. König H, Ponta H, Herrlich P. Coupling of signal transduction to alterna-
tive pre-mRNA splicing by a composite splice regulator. EMBO J (1998)
10:2904–13.
21. Matter N, Herrlich P, Konig H. Signal-dependent regulation of splicing via phos-
phorylation of Sam68. Nature (2002) 420:691–5. doi:10.1038/nature01153
22. Cheng C, Yaffe MB, Sharp PA. A positive feedback loop couples Ras activation
and CD44 alternative splicing. Genes Dev (2006) 20:1715–20. doi:10.1101/gad.
1430906
23. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-
mesenchymal transition generates cells with properties of stem cells. Cell (2008)
133:704–15. doi:10.1016/j.cell.2008.03.027
24. Xu Y, Gao XD, Lee JH, Huang H, Tan H, Ahn J, et al. Cell type-restricted activ-
ity of hnRNPM promotes breast cancer metastasis via regulating alternative
splicing. Genes Dev (2014) 28:1191–203. doi:10.1101/gad.241968.114
25. Yae T, Tsuchihashi K, Ishimoto T, Motohara T, Yoshikawa M, Yoshida GJ,
et al. Alternative splicing of CD44 mRNA by ESRP1 enhances lung
colonization of metastatic cancer cell. Nat Commun (2012) 3:883. doi:10.1038/
ncomms1892
26. Wielenga VJ, Van Der Neut R, Offerhaus GJ, Pals ST. CD44 glycoproteins in
colorectal cancer: expression, function, and prognostic value. Adv Cancer Res
(2000) 77:169–87. doi:10.1016/S0065-230X(08)60787-3
27. Uchino M, Kojima H, Wada K, Imada M, Onoda F, Satofuka H, et al. Nuclear
beta-catenin and CD44 upregulation characterize invasive cell populations
in non-aggressive MCF-7 breast cancer cells. BMC Cancer (2010) 10:414.
doi:10.1186/1471-2407-10-414
28. Zoller M. CD44: can a cancer-initiating cell profit from an abundantly expressed
molecule? Nat Rev Cancer (2011) 11:254–67. doi:10.1038/nrc3023
29. Dalerba P, Dylla SJ, Park IK, Liu R, Wang X, Cho RW, et al. Phenotypic charac-
terization of human colorectal cancer stem cells. Proc Natl Acad Sci U S A (2007)
104:10158–63. doi:10.1073/pnas.0703478104
30. Boon EM, Van Der Neut R, Van De Wetering M, Clevers H, Pals ST. Wnt signal-
ing regulates expression of the receptor tyrosine kinase met in colorectal cancer.
Cancer Res (2002) 62:5126–8.
31. Todaro M, Gaggianesi M, Catalano V, Benfante A, Iovino F, Biffoni M, et al.
CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving
colon cancer metastasis. Cell Stem Cell (2014) 14:342–56. doi:10.1016/j.stem.
2014.01.009
32. Baccelli I, Schneeweiss A, Riethdorf S, Stenzinger A, Schillert A, Vogel V, et al.
Identification of a population of blood circulating tumor cells from breast can-
cer patients that initiates metastasis in a xenograft assay. Nat Biotechnol (2013)
31:539–44. doi:10.1038/nbt.2576
33. Tavor S, Petit I, Porozov S, Avigdor A, Dar A, Leider-Trejo L, et al. CXCR4
regulates migration and development of human acute myelogenous leukemia
stem cells in transplanted NOD/SCID mice. Cancer Res (2004) 64:2817–24.
doi:10.1158/0008-5472.CAN-03-3693
Conflict of Interest Statement: The author declares that the research was conducted
in the absence of any commercial or financial relationships that could be construed
as a potential conflict of interest.
Received: 01 January 2015; accepted: 23 March 2015; published online: 08 April 2015.
Citation: Orian-Rousseau V (2015) CD44 acts as a signaling platform
controlling tumor progression and metastasis. Front. Immunol. 6:154. doi:
10.3389/fimmu.2015.00154
This article was submitted to Inflammation, a section of the journal Frontiers in
Immunology.
Copyright © 2015 Orian-Rousseau. This is an open-access article distributed under the
terms of the Creative Commons Attribution License (CC BY). The use, distribution or
reproduction in other forums is permitted, provided the original author(s) or licensor
are credited and that the original publication in this journal is cited, in accordance with
accepted academic practice. No use, distribution or reproduction is permitted which
does not comply with these terms.
Frontiers in Immunology | Inflammation April 2015 | Volume 6 | Article 154 | 4
